Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMB-I (Latrepirdine) for Mild to Moderate Alzheimer's Disease
NCT06292351Phase 2Completed
- Sponsor
- BIGESPAS Ltd
- Start
- Dec 2023
- Primary completion
- Jan 2025
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of latrepirdine in Alzheimer's disease (AD) (3 arms), sponsored by BIGESPAS Ltd. Primary endpoint: Mean change in Alzheimer's Disease Assessment Scale score at 26 weeks. Started Dec 2023; status: completed.
02
Drugs
latrepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06292351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06292351.